公开(公告)号：US20210301025A1

公开(公告)日：2021-09-30

申请号：US17303425

申请日：2021-05-28

Applicant: Janssen Biotech, Inc.

Inventor： Shalom GOLDBERG ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US20250099635A1

公开(公告)日：2025-03-27

申请号：US18832652

申请日：2023-01-25

Applicant: Janssen Biotech, Inc.

Inventor： Fei SHEN ,  Theresa MCDEVITT ,  Shalom GOLDBERG ,  Kristen WILLEY ,  Ryan M. SMITH ,  Sathyadevi VENKATARAMANI

IPC: A61K51/10

Abstract: Provided herein are immunoconjugates, such as radioimmunoconjugates, comprising a therapeutic moiety conjugated to an antibody or antigen binding domain with binding specificity for hK2. In certain embodiments, the hK2-specific immunoconjugate demonstrates a short half-life. Also provided herein are methods of using the immunoconjugates for selectively targeting cancer cells and for treating diseases such as prostate cancer.

公开(公告)号：US20190263915A1

公开(公告)日：2019-08-29

申请号：US16227597

申请日：2018-12-20

Applicant: Janssen Biotech, Inc.

Inventor： Shalom GOLDBERG ,  Steven JACOBS ,  Tricia LIN ,  Karyn O'Neil

IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US20250145646A1

公开(公告)日：2025-05-08

申请号：US18707865

申请日：2022-11-08

Applicant: JANSSEN BIOTECH, INC.

Inventor： Shalom GOLDBERG ,  Kristen WILEY ,  Rhys SALTER

IPC: C07F7/00 ,  A61K51/04 ,  A61K51/10

Abstract: The present invention is directed to compounds (macrocyclic compounds) and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in nuclear medicine as tracers and imaging agents.

公开(公告)号：US20230131727A1

公开(公告)日：2023-04-27

申请号：US17895295

申请日：2022-08-25

Applicant: Janssen Biotech, Inc.

Inventor： Shalom GOLDBERG ,  Donna KLEIN ,  Neeraj KOHLI ,  Theresa Marie MCDEVITT ,  Steven J. ORCUTT

IPC: C07K16/30 ,  A61P35/04 ,  A61K47/68

Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.